Zobrazeno 1 - 10
of 1 710
pro vyhledávání: '"High-risk neuroblastoma"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Objective High-risk neuroblastoma patients often have poor outcomes despite multi-treatment options. The risk stratification of high-risk MYCN-not-amplified (HR-MYCN-NA) patients remains difficult. This study aims to identify a gene set sign
Externí odkaz:
https://doaj.org/article/06e720ae708b4c0da602add253976c70
Publikováno v:
Current Oncology, Vol 31, Iss 6, Pp 3212-3226 (2024)
Neuroblastoma is a pediatric cancer with significant clinical heterogeneity. Despite extensive efforts, it is still difficult to cure children with high-risk neuroblastoma. Immunotherapy is a promising approach to treat children with this devastating
Externí odkaz:
https://doaj.org/article/b3c834f14f6c4248a411664e8223920c
Autor:
Philip Prathipati, Anup S. Pathania, Nagendra K. Chaturvedi, Subash C. Gupta, Siddappa N. Byrareddy, Don W. Coulter, Kishore B. Challagundla
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 35, Iss 2, Pp 101543- (2024)
Neuroblastoma is the most devastating extracranial solid malignancy in children. Despite an intense treatment regimen, the prognosis for high-risk neuroblastoma patients remains poor, with less than 40% survival. So far, MYCN amplification status is
Externí odkaz:
https://doaj.org/article/7d9eb9261b3e4d0b860be7a5cf90ac13
Autor:
Silvana Alfei, Paolo Giannoni, Maria Grazia Signorello, Carola Torazza, Guendalina Zuccari, Constantinos M. Athanassopoulos, Cinzia Domenicotti, Barbara Marengo
Publikováno v:
Nanomaterials, Vol 14, Iss 18, p 1505 (2024)
Neuroblastoma (NB) is a solid tumor occurring in infancy and childhood. Its high-risk form has currently a survival rate 50 values of 0.2 µM on HTLA-230 and 1.1 µM on HTLA-ER (538-fold lower than that of ETO) were already determined after 24 h of t
Externí odkaz:
https://doaj.org/article/1d8c868fbc224e908e858793ab59cf69
Autor:
A. Romiani, K. Simonsson, D. Pettersson, A. Al-Awar, N. Rassol, H. Bakr, D.E. Lind, G. Umapathy, J. Spetz, R.H. Palmer, B. Hallberg, K. Helou, E. Forssell-Aronsson
Publikováno v:
Heliyon, Vol 10, Iss 10, Pp e31409- (2024)
Background: Patients with high-risk neuroblastoma (NB) have a 5-year event-free survival of less than 50 %, and novel and improved treatment options are needed. Radiolabeled somatostatin analogs (SSTAs) could be a treatment option. The aims of this w
Externí odkaz:
https://doaj.org/article/d28f2510adf34997af7efed2df1db8f7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
BMC Pediatrics, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Despite multiple attempts have been made to develop risk stratification within high-risk neuroblastoma (NB) patients (age of diagnosis ≥ 18 month-old with metastatic NB), the definition of “ultra high-risk NB” is still lack
Externí odkaz:
https://doaj.org/article/19b39f29e4ba4ffd8e0b3aafd72dde20
Autor:
Irene Y. Cheung, Audrey Mauguen, Shakeel Modak, Ellen M. Basu, Yi Feng, Brian H. Kushner, Nai Kong Cheung
Publikováno v:
Vaccines, Vol 12, Iss 6, p 587 (2024)
The carbohydrate ganglioside GD2/GD3 cancer vaccine adjuvanted by β-glucan stimulates anti-GD2 IgG1 antibodies that strongly correlate with improved progression-free survival (PFS) and overall survival (OS) among patients with high-risk neuroblastom
Externí odkaz:
https://doaj.org/article/3b4e68713592493d99772656c5f94219
Autor:
Chiao-Hui Hsieh, Chen-Tsung Huang, Yi-Sheng Cheng, Chun-Hua Hsu, Wen-Ming Hsu, Yun-Hsien Chung, Yen-Lin Liu, Tsai-Shan Yang, Chia-Yu Chien, Yu-Hsuan Lee, Hsuan-Cheng Huang, Hsueh-Fen Juan
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 166, Iss , Pp 115429- (2023)
Neuroblastoma, a childhood cancer affecting the sympathetic nervous system, continues to challenge the development of potent treatments due to the limited availability of druggable targets for this aggressive illness. Recent investigations have uncov
Externí odkaz:
https://doaj.org/article/4b40b94a1f034bc0b617bd5fa477fa59
Autor:
Kezhe Tan, Jialin Mo, Meng Li, Yu Dong, Yujie Han, Xi Sun, Yingxuan Ma, Kai Zhu, Wei Wu, Li Lu, Jiangbin Liu, Kewen Zhao, Lei Zhang, Yujie Tang, Zhibao Lv
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-20 (2022)
Abstract Background Neuroblastoma (NB) is the most common extracranial solid tumor occurring during childhood and high-risk NB patients have a poor prognosis. The amplified MYCN gene serves as an important determinant of a high risk of NB. Methods We
Externí odkaz:
https://doaj.org/article/8ee7d1777fec4e1fb387432e02826486